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doi:10.1016/j.jtcvs.2004.01.041436 The Journal of Thoracic and CardioBackground: We prospectively evaluated a newly introduced minimal extracorpo-
real circulation system (Jostra MECC System; Jostra AG, Hirrlingen, Germany) for
aortic valve surgery.
Method: In a prospective, randomized study, 100 patients underwent aortic valve
replacement either with standard cardiopulmonary bypass (n 50, group B) or with
the MECC System (n  50, group B). The myocardial protection and the left vent
were identical for the two groups. The intrapericardial suction device was never
used (only the cell salvage device was used) to reduce the air-blood contact area.
Results: No significant differences were noted in patient characteristics and opera-
tive data between groups. Operative mortality (30 days) was 2% for group A and
4% for group B (difference not significant). From the preoperative period to the
postoperative period, the increase in C-reactive protein was significantly higher for
group B (P  .001). The postoperative troponin I level was significantly lower in
group A (mean 4.65  2.9 g/L at 24 hours) than in group B (8.2  4.4 g/L,
P  .03). On the other hand, the MECC System was associated with platelet
preservation. Renal function was better preserved and the neurologic event rate was
significantly lower for the MECC group (P  .02).
Conclusion: The MECC System is safe and allows aortic valve replacement under
the most favorable conditions. The system is more biocompatible than standard
cardiopulmonary bypass and provides a good postoperative biologic profile and
good clinical results, particularly for high-risk patients.
Since the beginning of the 1990s, cardiopulmonary bypass (CPB)circuits and cardioplegia procedures have achieved an optimal level.During this time, the complications related to CPB (inflammatoryresponse and renal, pulmonary, and neurologic complications) remainserious problems, even though their management has improved. Cor-onary artery bypass grafting (CABG) without CPB was therefore
introduced to avoid the deleterious effect of CPB. The new concept of CABG
without CPB has restarted the search for a new concept of a less aggressive and
more biocompatible CPB, minimal extracorporeal circulation (MECC). The Jostra
MECC System (Jostra AG, Hirrlingen, Germany) has been used for aortic valve
replacement (AVR) after a first clinical trial with CABG. We prospectively ran-
domly assigned 100 patients to be operated on with the MECC System (n  50) or
with standard CPB (n  50). This trial is the first randomized, prospective study
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deleterious effects of CPB is of prime necessity to maintain
satisfactory results after cardiac surgery as the patient pop-
ulation becomes more elderly and demonstrates more asso-
ciated pathologies.
Patients and Methods
From March 2001 to September 2002, we prospectively studied a
series of 100 patients who underwent isolated AVR operated on
with a standard CPB or with the MECC System. Associates
procedures such as CABG were excluded. The study conforms to
the ethical guidelines of Helsinki, as reflected by the approval of
local institution’s ethics committee.
Randomization
Patients were screened before AVR. Once written informed con-
sent had been obtained, patients were randomly assigned to un-
dergo AVR with either the MECC System (n  50, group A) or
standard CPB (n  50, group B). Exclusion criteria included
severe renal failure (creatinine 1.2 mg/dL) because of the pos-
sibility of perioperative hemofiltration and reoperative procedures.
The two groups of patients were similar with regard to the main
preoperative data (Table 1). The main preoperative, intraoperative,
and postoperative biologic and clinical data were collected to
evaluate the evolution of these parameters.
During an initial period, the MECC system used was totally
closed; AVR therefore could not be performed, because the left
ventricle could not be totally discharged. Subsequently, a suction
system was added to the circuit so that the AVR could be performed.
Anesthesia and Surgery Protocol
All patients received premedication with lorazepam (2.5 mg
orally) 90 minutes before operation, morphine sulfate (0.1 mg/kg
body weight intramuscularly), and ondansetron (8 mg orally) 60
minutes before transfer to the operating room. Anesthesia was
induced with midazolam (0.05-0.075 mg/kg), etomidate (0.3 mg/
kg), and sufentanyl. Neuromuscular block was induced by intra-
venous pancuronium (0.15 mg/kg) and was maintained by contin-
uous infusion of cisatracurium besylate (INN: cisatracurium
besilate, 1.5-2.0 g · kg1 · min1). Anesthesia was maintained
with propofol and a continuous infusion of remifentanil (0.2-1.0
g · kg1 · min1) or sufentanyl. A full heparin dose was given (3
mg/kg intravenously), and the activated clotting time was main-
tained above 400 seconds. With the MECC System circuit a half
dose (only 1.5 mg/kg) of heparin would have been sufficient. The
aortic and venous cannulas used were not precoated with heparin;
therefore a full dose of heparin was used for both groups. At the
end of the procedure, heparin was reversed with protamine at a 1:1
equivalent dose. Aprotinin was never used in this series.
The standard procedure was performed through a full median
sternotomy. The myocardial protection consisted in a hyperkale-
mic warm blood cardioplegia with the CP1B product (magnesium
chloride–potassium chloride–procaine chloride). This cardioplegic
solution was delivered every 20 minutes. The left vent was im-
planted into the main pulmonary artery trunk. For groups A and
group B, the mean aortic crossclamp and CPB times were, respec-
tively, 40.6  20.7 minutes and 71.2  23.5 minutes versus 45.6
The Journal of Thoraci 17.3 minutes and 77.2  27.3 minutes (difference not signifi-
cant). Fifty percent of the aortic prostheses implanted were bio-
prostheses (Table 1). Red blood cell transfusions were adminis-
tered if hematocrit fell below 25%.
Statistical Analysis
The statistical analyses were performed with the SPSS software
program (SPSS Inc, Chicago, Ill). All continuous data are ex-
pressed as mean  SD. The clinical profile of the two groups was
compared with analysis of the variance for continuous data and by
2 analysis or the Fisher exact test for categoric data. Analysis of
data with nonnormal distribution was performed with the Mann-
Whitney test.
MECC System
The Jostra MECC System (Jostra AG, Hirrlingen, Germany) is a
fully heparin-coated (Bioline-Jostra) closed-loop CPB system
(Figure 1). A half dose (150 U/kg intravenously) of heparin is
required. This system is composed of a membrane hollow-fiber
oxygenator (Quadrox) and a centrifugal pump (Rotaflow). The
tubing length does not exceed 1 m  2. The pump therefore must
be located near the patient’s head. The blood–foreign surface
contact area and the hemodilution are reduced with a 450-mL
priming solution. The system does not have cardiotomy suction.
Online blood gas and saturation monitoring and a heat exchanger
TABLE 1. Patient data
Group A (n  50) Group B (n  50)
Age (y, mean  SD) 67.8 10.8 66.6 10.7
Sex ratio (male/female) 3.05 3.27
Body mass index (kg/m2,
mean  SD)
1.86 0.17 1.88 0.23
Concomitant conditions (%)
Diabetes mellitus 15.3% 12.3%
Hypertension 36.7% 41.3%
Chronic obstructive
pulmonary disease
7.3% 8%
Moderate renal
insufficiency
5.3% 4.7%
Peripheral vascular
disease
10% 17.3%
Cerebrovascular
accident
3.3% 4%
Previous myocardial
infarction
4% 4.7%
Left ventricular ejection
fraction
Mean  SD 57.6% 3.4% 55.7% 4.8%
40% (%) 10.3% 12.7%
Mechanical prostheses
(No.)
Edwards-Mira 25 24
Bioprostheses (No.) 25 26
Toronto Stentless 15 14
Carpentier-Edwards 10 12
All differences are not statistically significant.are incorporated. The intrapericardial suction device was not used,
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salvage device. A double venous purse-string suture was system-
atically placed to ensure a perfect seal at the right atrial level
(deairing of the system is more difficult because of the absence of
venous reservoir). The MECC System was positioned closer to the
operative field because the circuit is shorter than standard CPB
(only 1 m). From 2002 on, a suction system was added to the
MECC System. This new system should be considered “semi-
closed” because of the partial air-blood contact through the suction
system. The myocardial protection used was a warm blood hy-
perkalemic cardioplegia with CP1B product (procaine).
Standard CPB
The CPB used was the same for all the patients (Figure 1). The line
Figure 1. Jostra MECC Systewas not coated with heparin. The CPB was primed with 1700 mL
438 The Journal of Thoracic and Cardiovascular Surgery ● SeptRinger lactate solution. The system contained a membrane oxy-
genator Cobe Optima (COBE Cardiovascular, Inc, Arvada, Colo)
and a standard roller pump. The tubing length was 2.20 m. The left
ventricular vent was implanted into the pulmonary artery as for the
MECC System. The intrapericardial suction device was not used,
and the intrapericardial blood was sucked in only with a cell
salvage device, as for the MECC System. The myocardial protec-
tion was similar to that used with the MECC System.
Results
Atrial fibrillation was the most frequent postoperative com-
plication in both groups (31% in group A and 36% in group
B, P .72) and was treated with amiodarone. The operative
mortalities (30 days) were 2% for group A and 4% for
ft) and standard CPB (right).group B (P  .2).
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required a 30-minute period of circulatory assistance with
inotropic drugs. Low cardiac output syndrome rates in
groups A and group B were 2% and 6%, respectively (P 
.03). In group A, 5 patients required dobutamine (5 g ·
kg1 · min1) or norepinephrine, and no IABCP was used.
In group B, 10 patients needed inotropic drugs (P  .02).
During the procedure, the mean blood pressure was
higher and more stable in group A (mean 71 mm Hg) than
in group B (mean 58 mm Hg, difference not significant).
During MECC and standard CPB hematocrit levels decrease
were 4.25% and 8.52%, respectively (P  .01). The peri-
operative red blood cell transfusion rates were 8.7% for
group A and 15.9% for group B (P  .01). The mean
postoperative blood loss volumes for groups A and B were
752.9  165.7 mL and 789.5  21 mL, respectively (dif-
ference not significant). From the preoperative period to the
patient discharge, the hemoglobin and hematocrits in group
A were stable, with only 0.82 g/L and 0.61% decreases,
respectively (Figure 2). In group B, there was a significantly
stronger decrease in hematocrit (Figure 2). After the first 48
hours, no significant differences were noted between the
two groups with respect to hemoglobin and hematocrit
evolution (Figure 2). The postoperative red blood cell trans-
fusion rates in the two groups were therefore similar (7%
and 9% for groups A and B, respectively, difference not
significant).
The evolution of platelet and leukocyte counts were
correlated with a stronger inflammatory syndrome in group
B (CPB) (Table 2). Likewise, the increase in C-reactive
protein was higher for group B between the preoperative
Figure 2. Hemoglobin evolution. 1, Preoperative; 2, after CPB or
MECC; 3, postoperative hour 6; 4, postoperative day 1; 5, postop-
erative day 2; 6, discharge. Hemoglobin level was significantly
lower after MECC (light bars) than after standard CPB (dark bars).
Asterisk indicates P < .05.and postoperative periods (Table 2). The postoperative tro-
The Journal of Thoraciponin I level was significantly lower in group A (MECC)
(mean 4.65  2.9 g/L in the first 24 hours) than in group
B (9.5  4.4 g/L, P  .03; Figure 3).
The mean time to extubation for group A was 8.8  4.1
hours, lower than that for group B (8.2  5.1 hours, differ-
ence not significant). The mean intensive care stay for group
A was 42.2  3.6 hours, also lower than that for group B
(48.2  4.3 hours, difference not significant). From the
intensive care unit, the patients were transferred to the
surgery unit for mean stays of 6.2  3.3 days for group A
and 6.5  2.4 days for group B (difference not significant).
Patients in group B had significantly higher postopera-
tive levels of creatinine and urea (Table 2). Consistent with
this, group B required more diuretics than did group A (22%
vs 9.5 %, P  .01). Three patients in group B and only 1 in
group A required hemofiltration (difference not significant).
Postoperative focal neurologic complications (aphasia, fo-
cal motor, sensory cranial abnormality) and altered mental
status (mainly disorientation) were significantly (P  .02)
more frequent in group B (n  7) than in group A (n  2).
Discussion
Since the early 1990s, the patients admitted for and operated
on in cardiac surgery have had an increase in risk, with a
higher mean Parsonnet score. In fact, older age at operation
and respiratory or renal insufficiencies are not longer con-
sidered exclusion criteria. Improvements in surgical, anes-
thesia, and CPB techniques are all important in achieving
satisfactory postoperative results despite of worsening pre-
TABLE 2. Biologic data
Group A
(n  50)
Group B
(n  50)
P
value
Leukocytes (cells/mm3)
Preoperative 7950 2540 7530 3200 NS
Postoperative h 6 12.900 3510 13.900 2820 NS
Postoperative d 5 8600 2340 8230 3200 NS
Platelets (cells/mm3)
Preoperative 245.182 32.254 251.581 42.400 NS
Postoperative h 6 179.142 21.320 122.910 24.350 .04
Postoperative d 5 221.285 41232 215.342 32.600 NS
Creatinine (mg/dL)
Preoperative 78 17.2 79 12.5 NS
Postoperative h 6 88 22.2 98.5 24.3 .03
Postoperative d 5 83 27.2 88 25.2 NS
Urea (mmol/L)
Preoperative 7.2 2.1 7.4 2.1 NS
Postoperative h 6 10.4 3.4 12.3 4.8 .02
Postoperative d 5 7.6 2.1 8.1.3 4 NS
C-reactive protein
(mg/L)
Preoperative 7.5 2.2 6.4 3.3 NS
Postoperative h 72 39.5 18.5 68.6 28.5 .001
NS, Not statistically significant.operative clinical status of the patient population.
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involves a pathophysiologic response similar to that of
posttraumatic shock, the so-called postperfusion syndrome,
which may lead to the systemic inflammatory response
syndrome, adult respiratory distress syndrome, sepsis, and
multiorgan failure.1-3 To improve biocompatibility, artificial
surfaces are heparin coated with various materials in an
effort to mimic the natural endothelial surface. The centrif-
ugal pump also may improve the biocompatibility, as may
exclusive use of the cell salvage device to limit the air-blood
contact area.4 The MECC System combines these elements,
which could explain inflammatory syndrome decrease5 and
the good clinical and biologic results described in this
prospective series.
Heparin-coated artificial surfaces was first used by Gott.
The evidence that use of surface-heparinized equipment
would avoid the need for full systemic heparinization led to
the introduction of heparin-coated CPB circuits in combi-
nation with reduced systemic heparin levels.6-9 Currently
available heparin-coated circuits have been reported to be
associated with reduced expression of systemic inflamma-
tory response syndrome; reduced activation of neutrophils,
monocytes, eosinophils, platelets, and the complement sys-
tem; and limitation of cytokine release and reduced stimu-
lation of the coagulation system.8 In our series, the full
heparin dose was given. Nevertheless, in our prospective
trial we have shown for AVR surgery better clinical results,
Figure 3. Troponin T evolution. 1, Postoperative hour 3; 2, post-
operative day 1; 3, postoperative day 2. Troponin T level was
significantly lower with MECC during postoperative period. This
result outlines better preservation of myocardial preservation
with MECC System (light bars) than with standard CPB (dark
bars). Asterisk indicates P < .05.preservation of renal function, reduced cardiac enzyme re-
440 The Journal of Thoracic and Cardiovascular Surgery ● Septlease, and better preservation of platelet count. Indeed, the
MECC System represents the successful combination of
decreased deleterious CPB effects (as in off-pump CABG)
and CPB advantages for hemodynamic and surgical proce-
dure management. The inflammatory syndrome is espe-
cially reduced because of decreased hemodilution10,11 and
air-blood contact area reduction.12 The decreased S100
protein release during MECC versus standard CPB might
show a lesser neurologic toxicity associated with
MECC.13,14 The inflammatory syndrome is reduced with
the MECC System, as shown by Fromes and colleagues.5
We therefore can expect reduced postoperative morbidity.
The patients operated on for AVR are often included in
high-risk patient groups: age older than 65 years, renal
dysfunction, and respiratory failure. The MECC System is
therefore particularly interesting for AVR. In our prospec-
tive, randomized trial, the postoperative biologic and clini-
cal data evolution were better for the MECC group, partic-
ularly for high-risk patients. Thus in elderly patients the
MECC System could reduce the renal effect and cerebral
injury well described in previous studies.13-15 The lowering
of inflammatory syndrome and thus greater hemodynamic
stability during the procedure could explain the results for
renal and neurologic preservation.
Use of the MECC System as a “semiclosed” system with
aortic and pulmonary artery vent allowed AVR to be per-
formed without losing its biologic advantage, as shown in
this study. The left ventricular vent for performing the AVR
is implanted in the pulmonary artery trunk, rather than
directly in the left ventricle, to reduce the air-blood contact
area during aortic crossclamping. The vent could be im-
planted in the left atrium with a low depression to avoid
air-blood contact.
A learning curve for this technique is necessary for the
surgical and anesthetic team. The MECC System offers less
safety than standard CPB because of the absence of venous
reservoir. A risk of gas embolism exists if there is an
air-intake on the venous side. We therefore performed two
purse-string sutures on the venous side. Currently, we have
performed 400 procedures with the MECC System, and we
have encountered 3 cases of air intake on the venous side.
None of these 3 adverse events had consequences for the
patients. In all cases deairing was achieved without any
problems, and the air was stopped on the anterior part of the
oxygenator.
We have performed a few mitral operations with the
MECC System. However, a suction device is necessary to
drain the operative field into the left atrium, because the
blood volume is too high to suck in to the cell salvage
device. For mitral procedures, the left vent in the pulmonary
artery is not sufficient and a left intra-atrial vent is neces-
sary.
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The Jostra MECC System is safe, allowing AVR surgery
under optimal conditions. The system is more biocompat-
ible than standard CPB and provides a good postoperative
biologic profile and good clinical results, particularly for
high-risk patients.
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